Details

Autor(en) / Beteiligte

• Bhatia, Kunal
• Akhtar, Iqra N.
• Akinci, Yasemin
• Liaqat, Jahanzeb
• Siddiq, Farhan
• Gomez, Camilo R.
• Qureshi, Adnan I.

Titel

Drug‐Eluting Balloon Angioplasty for In‐Stent Restenosis Following Carotid Artery Stent Placement

Ist Teil von

• Journal of neuroimaging, 2020-05, Vol.30 (3), p.267-275

Ort / Verlag

United States: Wiley Subscription Services, Inc

Erscheinungsjahr

2020

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• ABSTRACT BACKGROUND AND PURPOSE Drug‐eluting balloons (DEBs) have been proposed as an option for the treatment of in‐stent restenosis (ISR) following carotid artery stent placement. We report our experience and review of literature to provide additional data. METHODS For literature review, PubMed search was conducted to identify studies published between 2005 and 2019, reporting data on management of carotid ISR with DEBs. Two cases with carotid ISR, which were successfully treated with DEB at our facility, were also included in the final compilation of results RESULTS A total of seven studies demonstrating the use of the DEBs for treatment of carotid ISR were identified. They encompassed 31 patients, 11 (35.5%) of whom presented with symptomatic ISR, with the remaining 20 patients (64.5%) asymptomatic. DEB angioplasty followed by stent placement was performed in 3 patients, whereas DEB alone was utilized in 28 patients. Periprocedural complications included asymptomatic dissection from DEB inflation in 1 patient and transient neurological deficits in another patient. Follow‐up period was variable and ranged from 1 month to 5 years. Three patients were noted to develop recurrent asymptomatic stenosis, whereas 1 patient developed an episode of symptomatic restenosis post procedural on follow‐up. In our two cases, both patients were noted to have protracted period of hypotension postprocedure without any new or recurrent neurological symptoms. CONCLUSION The use of DEBs is a promising development and a viable alternative for management of severe and recurrent carotid ISR.